The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now.

[1]  M. Shipp,et al.  Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Millenson,et al.  Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Y. Natkunam,et al.  PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Ansell.  Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma? , 2016, Journal of oncology practice.

[5]  Y. Jeon,et al.  Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma , 2016, Tumor Biology.

[6]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[7]  M. Pfreundschuh,et al.  Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. , 2016, Blood.

[8]  J. Rosenberg,et al.  IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). , 2016 .

[9]  S. Ansell,et al.  Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma , 2016, Cancer journal.

[10]  T. Kipps,et al.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.

[11]  Patricia A. Young,et al.  Analysis of Programmed Death Ligand 1 (PD-L1) Expression in Diffuse Large B Cell Lymphomas (DLBCL) in HIV-Negative Versus HIV-Positive Patients , 2015 .

[12]  M. Ebinger,et al.  Leukemia Related Co-Stimulation / Co-Inhibition Predict T-Cell Attack of Acute Lymphoblastic Leukemia Mediated By Blinatumomab , 2015 .

[13]  K. Akashi,et al.  Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. , 2015, Blood.

[14]  R. Brentjens,et al.  CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date , 2015, Cancer journal.

[15]  D. Davar,et al.  PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV , 2015, Case reports in oncological medicine.

[16]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[17]  Jian Huang,et al.  PD-L1 and Survival in Solid Tumors: A Meta-Analysis , 2015, PloS one.

[18]  S. Paydaş,et al.  Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma , 2015, Annals of Hematology.

[19]  Patrick Schöffski,et al.  Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). , 2015 .

[20]  E. Hawkes,et al.  Programmed cell death-1 inhibition in lymphoma. , 2015, The Lancet. Oncology.

[21]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[22]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[23]  R. Advani,et al.  Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. , 2015, Blood.

[24]  H. Kohrt,et al.  Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK , 2015, Proceedings of the National Academy of Sciences.

[25]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[26]  J. Gershan,et al.  Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma , 2015, Journal of Immunotherapy for Cancer.

[27]  Andrew J. Dunford,et al.  Targetable genetic features of primary testicular and primary central nervous system lymphomas. , 2014, Blood.

[28]  M. Shipp,et al.  PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013) , 2014 .

[29]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[30]  K. Kinzler,et al.  Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells , 2014, Proceedings of the National Academy of Sciences.

[31]  J. Byrd,et al.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.

[32]  K. Tarte,et al.  High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial , 2014, Leukemia.

[33]  A. Zelenetz,et al.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.

[34]  H. Abken,et al.  Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  L. Gordon,et al.  Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Gascoyne,et al.  Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. , 2013, Blood.

[37]  T. Okazaki,et al.  A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application , 2013, Nature Immunology.

[38]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[39]  J. Gershan,et al.  Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma , 2013, The Journal of Immunology.

[40]  S. Gettinger,et al.  A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). , 2013 .

[41]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[42]  S. Quezada,et al.  Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer , 2013, British Journal of Cancer.

[43]  Ash A. Alizadeh,et al.  High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. , 2013, Blood.

[44]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[45]  Scott E. Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  W. Wilson,et al.  Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations , 2011, Modern Pathology.

[47]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[48]  Alexandra G. Smith,et al.  Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network , 2011, British Journal of Cancer.

[49]  R. Levy,et al.  Active and passive immunotherapy for lymphoma: proving principles and improving results. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  G. Pinkus,et al.  Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells , 2011, Clinical Cancer Research.

[51]  A. Eggermont,et al.  Autoimmunity and treatment outcome in melanoma , 2011, Current opinion in oncology.

[52]  Alexandra G. Smith,et al.  Epidemiology of lymphomas , 2011, Histopathology.

[53]  Michael R. Green,et al.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.

[54]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[55]  J. Taube,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Loise M. Francisco,et al.  The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.

[57]  S. Pileri,et al.  WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. , 2010, Pathologica.

[58]  T. Honjo,et al.  Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma , 2010, Cancer.

[59]  R. Warnke,et al.  PD-1 Expression in T-cell Lymphomas and Reactive Lymphoid Entities: Potential Overlap in Staining Patterns Between Lymphoma and Viral Lymphadenitis , 2010, The American journal of surgical pathology.

[60]  T. Habermann,et al.  Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma , 2009, Clinical Cancer Research.

[61]  A. Feldman,et al.  B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. , 2009, Blood.

[62]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[63]  L. Xerri,et al.  Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. , 2008, Human pathology.

[64]  R. Berger,et al.  Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies , 2008, Clinical Cancer Research.

[65]  K. Kabashima,et al.  Augmented expression of programmed death‐1 in both neoplastic and non‐neoplastic CD4+ T‐cells in adult T‐cell leukemia/lymphoma , 2007, International journal of cancer.

[66]  T. Zander,et al.  RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma. , 2007, Blood.

[67]  S. Riddell,et al.  Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. , 2007, Human gene therapy.

[68]  W. Klapper,et al.  Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. , 2007, Haematologica.

[69]  B. Quesnel,et al.  Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. , 2007, Blood.

[70]  A. Mackensen,et al.  Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro , 2006, International journal of cancer.

[71]  G. Freeman,et al.  Programmed Death-1 (PD-1) is a Marker of Germinal Center-associated T Cells and Angioimmunoblastic T-Cell Lymphoma , 2006, The American journal of surgical pathology.

[72]  G. Zhu,et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.

[73]  T. Honjo,et al.  PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. , 2004, International immunology.

[74]  M. Nishimura,et al.  B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression , 2004, Clinical Cancer Research.

[75]  L. Staudt,et al.  Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.

[76]  G. Freeman,et al.  Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. , 2002, Immunology letters.

[77]  D. Pardoll,et al.  B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells , 2001, The Journal of experimental medicine.

[78]  S. Markovic,et al.  Immune reconstitution after autologous hematopoietic stem cell transplantation. , 2001, Mayo Clinic proceedings.

[79]  T. Habermann,et al.  Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[81]  B. Dörken,et al.  A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. , 2000, Blood.

[82]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[83]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[84]  Z. Eshhar,et al.  Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anti-collagen antibody and Fc epsilonRI-signaling gamma subunit. , 1998, Journal of immunology.

[85]  D. Rubinstein,et al.  Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. , 1998, Blood.

[86]  M. Mack,et al.  A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[87]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[88]  A. Younes,et al.  Novel immunotherapies in lymphoid malignancies , 2016, Nature Reviews Clinical Oncology.

[89]  L. Gordon,et al.  Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy. , 2015, Blood reviews.